PBRM1 mutations may be a potential genomic biomarker to predict response to ICI treatment in patients with mRCC, mainly in second- and later treatment lines...This systematic review showed an association between truncated PBRM1 mutations and superior efficacy with ICI in patients with mRCC predominantly clear cell histology, receiving nivolumab as second- or later treatment lines, but not in those in the first-line setting.